(CercleFinance.com) – Nicox announced on Monday that a patent for NCX 470, its experimental glaucoma treatment, had been issued by Chinese authorities, extending product coverage to 2039.
NCX 470, its lead drug candidate in development, is a novel nitric oxide-donating prostaglandin analog designed to deliver bimatoprost and nitric oxide to the eye.
It aims to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
The results of two phase III clinical studies on the product are expected in the first quarter of 2023 and by the end of 2023.
With equivalent patents already granted in the United States and Europe, the formulation of NCX 470 is now protected in the largest territories worldwide.
Nicox shares are currently up 1.2% on the Paris Stock Exchange.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
